NCT02354534 - Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

November 6, 2018

Conditions

Cervical Intraepithelial Neoplasia Grade 2/3High-risk HPV (Any Strain)

Interventions

DRUG

Artesunate Suppositories

Trial Locations (3)

Greater Baltimore Medical Center, Towson

Johns Hopkins Outpatient Center, Baltimore

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore